Hayes News

Hayes News Service keeps our clients up to date with late-breaking news from clinical trials, coverage decisions, and new product approvals. We focus on emerging technologies with potentially high clinical and financial impact as soon as they are announced publicly.

Our analysts scan more than 75 peer-reviewed journals and news briefings from government agencies, medical associations, and research institutes. Results of selected studies or articles are summarized and posted with a brief commentary on whether the findings are likely to have a substantial impact.

    FDA Authorizes Drug Combination for Treatment of COVID-19

    The Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressi…

    read more

    FDA Issues EUA for Drug Combination for Treatment of COVID-19

    The Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for baricitinib (Eli Lilly and Company) in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric patients 2 years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal memb…

    read more

    WHO Recommends Against Use of Remdesivir in COVID-19

    The World Health Organization (WHO) has issued a conditional recommendation against the use of remdesivir in hospitalized patients, regardless of disease severity, citing a lack of evidence that remdesivir improves survival and other outcomes in these patients.

    read more

    COVID-19 Vaccine Candidate Achieved Success in First Interim Analysis

    Pfizer Inc. and BioNTech SE have announced an interim analysis from a phase III trial of their COVID-19 vaccine candidate. Based on the first interim efficacy analysis, the mRNA-based vaccine candidate, BNT162b2, has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection.

    read more